Pricing · healthcare · emerging marketsJul 20269 min read340 words

The 12 most common packaging and tiers mistakes and how to fix them for healthcare and life sciences in emerging markets

Every mistake we see teams make with packaging and tiers — starting with the ones that cost the most and are the cheapest to fix. Written for commercial leaders at healthtech, medtech, and life-sciences companies in emerging markets.

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in emerging markets. In this market, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint, so the way you install packaging and tiers has to be shaped to that reality from day one.

Every packaging and tiers failure we have investigated maps to one of the mistakes below. They repeat because they are structurally easy to make.

Mistake one, the foundational one: three tiers labelled small, medium, large that mean nothing. Fix by naming an owner and writing kill criteria before you spend a dollar.

Mistake two: mistaking volume for progress. Fix by making average contract value by tier the only weekly headline number.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in emerging markets it is compounded by the fact that operating footprint and pricing fit, not brand awareness is what actually gates growth. Packaging and tiers is only useful here when it is pointed at both constraints at once.

Mistake three: buying tools before defining the workflow. Fix by drawing the workflow on paper first and buying only what the paper shows.

Mistake four: shipping without a quality gate. Fix by requiring a human eyeball on every artefact for the first four weeks.

Mistake five: ignoring the trigger. Packaging and tiers works when the wrong tier structure caps deal size for years; without a real trigger the model is guesswork.

Mistake six through twelve: cascade from the first five. Fix the top five and most of the others resolve themselves inside a month.

Concretely for healthcare and life sciences in emerging markets: the healthcare teams that install this get past procurement instead of dying in it, and the teams that install this early own the category before Western vendors even show up. That is the reason it is worth installing packaging and tiers deliberately for this market rather than importing a playbook designed for somewhere else.

SaaS packagingpricing tiersproduct bundlesSaaS packaging mistakesSaaS packaging pitfallsSaaS packaging for healthcare and life sciencesSaaS packaging in emerging marketshealthcare and life sciences growth in emerging markets

Frequently asked questions

Pricing · healthcare · emerging markets — answered

Does packaging and tiers work for healthcare and life sciences in emerging markets?
Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint. The healthcare teams that install this get past procurement instead of dying in it.
What is the most expensive packaging and tiers mistake?
Three tiers labelled small, medium, large that mean nothing — because it silently degrades every downstream metric.
Which mistake is cheapest to fix?
Missing kill criteria. Write them in an hour and save a quarter of budget.
Can I skip the quality gate?
Not in the first four weeks. After the model is proven, you can automate parts of it.
How do I know a mistake is compounding?
Average contract value by tier stalls or drops for two consecutive weeks. That is your alarm.
What is the emerging markets-specific pitfall when running packaging and tiers for healthcare?
Importing a playbook that was built for another market. In emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint — the install has to reflect that.

Growth Broker editorial

Filed under pricing · healthcare · emerging markets

Up next

AI for Growth: the complete 2026 guide for B2B companies

Read piece

Ready to broker your growth?

Book a Growth Call